LOS ANGELES, Nov. 30 /PRNewswire-FirstCall/ -- Signalife, Inc. announced that The United States Patent and Trademark Office has awarded to the company patent #7,299,083 entitled “Electrode For, And Method Of, Indicating Signal Characteristics At Particular Positions In A Patient’s Body”. This patent, which covers 56 patent claims, is one of several patents filed by Signalife over the last five years.
Dr. Budimir S. Drakulic, Signalife’s Chief Technology Officer, stated: “At the company’s inception we carefully assessed the field of electrocardiography and electrocardiographic devices. Each aspect of electrocardiographic monitoring was scrutinized. Based on the knowledge gained during this assessment process, we developed a solution for ultimate electrocardiographic devices. Patent applications were filed for patents only upon the complete verification of the underlying scientific principles. I am very proud of our research and development team, which has developed a very significant patent portfolio. Under the leadership of Dr. Lowell Harmison, our new CEO, we are now making an important impact in the cardiac market”.
About Signalife
Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.
Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are “forward- looking” statements. Forward-looking statements involve known and unknown risks, which may cause Signalife’s actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife’s technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife’s technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife’s technology, and the unavailability of financing to complete management’s plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife’s technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife’s filings with the Securities and Exchange Commission.
CONTACT: John Woodbury, outside counsel, Signalife, +1-818-337-2601,
john@jmwoodburylaw.com
Web site: http://www.signalife.com//
